BICYCLIC SULFONAMIDE DERIVATIVES AND THEIR PREPARATION, THEIR USE AND FORMULATIONS CONTAINING THEM

Abstract: Bicyclic sulfonamide derivatives represented by the formula: (wherein R₁ is hydrogen or lower alkyl; R₂ is lower alkyl, aralkyl, or aryl which may be substituted by lower alkyl, alkoxy, acetoxy, hydroxy, halogen, nitro or phenyl; and the wavy line indicates the R or S configuration or their mixture), or their salts, are new compounds useful as antithrombotic, antivasoconstricting, and antibronchoconstricting drugs.

Description: The present invention relates to new compounds which may be used as medicines for improving symptoms caused by thromboxane and to their production. In more detail, this invention relates to novel pinane type sulfonamide derivatives to which an unsaturated fatty acid is attached. The compounds of the present invention may be used as antithrombotic, anti-vasoconstricting, and anti-bronchoconstricting drugs. The general course of atherosclerosis, which is regarded as the main risk factor of myocardial infarction and cerebral infarction, begins in the arterial intima with mucoid accumulation and fibroblast formation, progressively followed by degeneration, deposition of lipid and cholesterol and destruction and atheromasia of the intima tissue, with gradual formation of high-degree and localized hypertrophy in the intima. Atherosclerosis has long been regarded as caused by thrombus formation and fibrin deposition, but recent discoveries of thromboxane A₂ (TXA₂) by Samuelsson et al. and prostacycline (PGI₂) by Vane et al. have revealed an interaction between platelets and the vessel wall. Platelets are said to play an important role in the onset and progress of atherosclerosis. Therefore, it is now recognized that the use of antithrombotic drugs, particularly drugs which inhibit platelet aggregation, are effective for the treatment of atherosclerotic diseases. In addition to conventional antithrombotic drugs such as heparin and coumarin compounds, certain types of prostaglandins are know to have a potent platelet aggregation inhibitory action. From these facts, prostaglandin derivatives have attracted much attention as possible, antithrombotic drugs. For example, analogues of prostaglandin E₁ and I₂ receptor agonists have been developed. Since thromboxane A₂ shows potent platelet aggregation and vasoconstriction action, thromboxane A₂ synthesis inhibitors, such as cyclooxygenase inhibitors and thromboxane synthetase inhibitors, and thromboxane A₂ receptor antagonists, have been developed. Thromboxane A₂ receptor antagonists include 13-APA (Venton D.L. et al., J. Med. Chem., 22 , 824 (1979)), PTA₂ (Lefer A.M. et al., Proc. Natl. Acad. Sci. U.S.A., 76 , 2566 (1979)), BM-13177 (Lefer A.M. et al., Drugs of Today, 21 , 283 (1985)), SQ-29548 (Ogletree et al., J. Pharmacol. Exp. Ther., 34 , 435, (1985)) or the like. Thromboxane A₂ receptor antagonists are also disclosed in Japan Kokai No. 83-13551, Japan Kokai No. 86-49, USP 4,654,357 or the like. When thrombin acts on platelets, cyclooxygenase is activated. By activation of cyclooxygenase, thromboxane A₂ is produced enzymatically in platelets, the vessel wall, and various other cells, from arachidonic acid through prostaglandins G₂ and H₂. This product has various potent physiological or pathogenic actions. In particular, potent platelet aggregation action and action constricting the smooth muscle of the bronchi, and of the coronary, cerebral and pulmonary arteries, etc. are considered to be the factors which relate to the onset and progress of such circulatory and respiratory diseases as angina pectoris, myocardial infarction, cerebral infarction, and bronchial asthma. Moreover, it is said that strong action occurs even at a concentration of 10⁻¹⁰ to 10⁻¹¹ M. therefore, increasing attention has been paid to the development of thromboxane A₂ antagonists or inhibitors as anti-thrombotics, anti-vasoconstrictives or anti-bronchoconstrictives. Inhibitors, however, have some problems since they influence prostaglandins which bear various important roles other than thromboxane A₂ and uncontrollable thromboxane-like harmful effects are caused by accumulated substrates such as prostaglandin H₂ Thus, the development of antagonists has been especially sought. This invention provides bycyclic sulfonamide derivatives represented by the formula: (wherein R₁ is hydrogen or lower alkyl; R₂ is lower alkyl, aralkyl, or aryl which may be substituted by lower alkyl, alkoxy, acetoxy, hydroxy, halogen, nitro or phenyl; and the wavy line indicates the R or S configuration, or their mixture), or their salts. These compounds may be used as antithrombotic, antivasoconstricting and antibronchoconstricting drugs. This invention is based upon the synthesis of the bicyclic sulfonamide derivatives represented by the general formula (I) and the salts thereof, and the finding that these new compounds have potent activity as thromboxane A₂ receptor antagonists, and are chemically and biochemically stable. The compounds of the present invention can be prepared by the following processes A and B. Process A One process for preparing a compound of the formula: (wherein R₁ is hydrogen or lower alkyl; R₂ is lower alkyl, aralkyl or aryl which may be substituted by lower alkyl, alkoxy, acetoxy, hydroxy, halogen, nitro or phenyl; and the wavy line indicates the R or S configuration or their mixture), or salts thereof, comprises reacting a compound of the formula: (wherein R′₁ is lower alkyl; and the wavy line is as defined above), or salt thereof, with a compound of the formula: Hal-SO₂-R₂ (wherein Hal is halogen; and R₂ is as defined above) and, if desired, subjecting the resulting compound to hydrolysis and/or salt formation. Process B Another process for preparing a compound of the formula: (wherein R₁ is hydrogen or lower alkyl; R₂ is lower alkyl, aralkyl or aryl which may be substituted by lower alkyl, alkoxy, acetoxy, hydroxy, halogen, nitro or phenyl; and the wavy line indicates the R or S configuration or their mixture), or salts thereof, comprises reacting a compound of the formula: (wherein R₂ and the wavy line are each as defined above), or its equivalent, with a compound of the formula: (Ar)₃P=CH-(CH₂)₃COOR₁ (wherein Ar is aryl; and R₁ is as defined above) and, if desired, subjecting the resulting compound to esterfication, hydrolysis and/or salt formation. The following lists exemplify various terms used throughout this specification. The term "lower alkyl" includes both straight and branched C₁-C₅ alkyl, e.g., methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, pentyl or the like. The term "alkoxy" includes C₁-C₅ alkloxy, e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy or the like. The term "aryl" includes phenyl, naphthyl, poly aromatic hydrocarbons or the like. The term "aralkyl" includes lower alkyl substituted by aryl, e.g., benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpropyl or the like. The term "aryl" when represented by "Ar" includes phenyl or substituted phenyl, e.g., tolyl, methoxyphenyl or the like. The term "halogen" refers to fluorine, chlorine, bromine, or idodine. The term "equivalent" means a tautomer. In the general formulae, R₁ is hydrogen or lower alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl or the like. The preferred R′, lower alkyl, is methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl or the like. The preferred R₂ is lower alkyl, aralkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl or benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl or the like, or aryl which may be substituted by lower alkyl, alkoxy, acetoxy, hydroxy, halogen, nitro or phenyl, e.g., phenyl, naphthyl, 4-tolyl, 4-ethylphenyl, 4-propylphenyl, 4-isopropylphenyl, 4-tert-butylphenyl, 2-methoxyphenyl, 4-methoxyphenyl, 4-ethoxyphenyl, 4-propoxyphenyl, 4-acetoxyphenyl, 4-hydroxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-nitrophenyl, 4-nitrophenyl or the like. The preferred Hal, halogen, is chlorine, bromine or iodine. The preferred Ar is phenyl or substituted phenyl, e.g., tolyl, methoxyphenyl or the like. An especially preferred R₁ is hydrogen or methyl. An especially preferred R′₁ is methyl. Especially preferred R₂ groups are methyl, benzyl, phenethyl, 3-phenylpropyl or the like, or phenyl, naphthyl, 4-tolyl, 4-ethylphenyl, 2-methoxyphenyl, 4-methoxyphenyl, 4-acetoxyphenyl, 4-hydroxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-nitrophenyl or the like. Especially preferred Hal is chlorine. Especially preferred groups Ar are phenyl or substituted phenyl, e.g., tolyl or the like. The amine salts include, for example, salts with trifluoroacetic acid or the like. Furthermore, the salts of the present compounds represented by the general formula (I) include, for example, salts with alkali metals such as lithium, sodium, and potassium, salts with alkaline earth metals such as calcium, ammonium salts, salts with organic bases such as triethylamine, 2-aminobutane, tert-butylamine, diisopropylethylamine, n-butylmethylamine, n-butyldimethylamine, tri-n-butylamine, dicyclohexylamine, N-isopropylcyclohexylamine, furfurylamine, benzylamine, methylbenzylamine, dibenzylamine, N,N-dimethylbenzylamine, 2-chlorobenzylamine, 4-methoxybenzylamine, 1-naphthlenemethylamine, diphenylamine, triphenylamine, 1-naphthylamine, 1-aminoanthracene, 2-aminoanthracene, dehydroabietylamine, N-methylmorpholine, pyridine, and salts with amino acids such as lysine and arginine. Illustrative compounds of the present invention are given below:- 7-(6,6-dimethyl-2-phenylmethanesulfonamidobicyclo[3.1.1]hept-3-yl)-5-heptenoic acid, 7-[6,6-dimethyl-2-(2-phenylethanesulfonamido)bicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[6,6-dimethyl-2-(3-phenylpropanesulfonamido)bicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[2-(2-chlorobenzenesulfonamido)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-(6,6-Dimethyl-2-methanesulfonamidobicyclo[3.1.1]hept-3-yl)-5-heptenoic acid, 7-[2-(3-chlorobenzenesulfonamido)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[2-(4-chlorobenzenesulfonamido)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[6,6-dimethyl-2-(4-fluorobenzenesulfonamido)bicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[6,6-dimethyl-2-(4-ethylbenzenesulfonamido)bicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[6,6-dimethyl-2-(4-nitrobenzenesulfonamido)bicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[6,6-dimethyl-2-(4-methoxybenzenesulfonamido)bicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[2-(4-acetoxybenzenesulfonamido)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[6,6-dimethyl-2-(4-hydroxybenzenesulfonamido)bicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[6,6-dimethyl-2-(4-toluenesulfonamido)bicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[2-(4-biphenylsulfonamido)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, 7-[6,6-dimethyl-2-(2-naphthalenesulfonamido)bicyclo[3.1.1]hept-3-yl]-5-heptenoic acid, and their carboxylate esters and salts. The compounds of the present invention represented by the general formula (I) include all the possible stereoisomeric forms (e.g., diastereomer, epimer, enantiomer or the like). Among the stereoisomers which are included in the compounds of the present invention (I), the 5(E) and 5(Z) isomers can be shown by the following formulae. (In the following formulae, only one enantiomer is shown.) The starting materials for processes A and B can be prepared in accordance with the following reaction sequences, in which details of the manner in which processes A and B may be carried out are given. Process-I (Preparation of Ia, Ib, Ic or Ie) (Step I) In this step, the aldehyde equivalent V is allowed to react with an ylide in accordance with the Wittig reaction to give the compound IV . The ylide used may be prepared by base treatment of a phosphonium salt which has been prepared from a 5-halogenopentanoic acid by reaction with triphenylphosphine. For the base treatment, sodium dimsyl, potassium dimsyl, potassium tert-butoxide, sodium hydride, n-butyl lithium or lithium diisopropylamide is exemplified as a base. As the 5-halogenopentanoic acid, 5-chloropentanoic acid, 5-bromopentanoic acid or the like is exemplified. This step can be carried out in a solvent such as an ether,( e.g., ethyl ether, tetrahydrofuran), n-hexane or dimethylsulfoxide at a temperature of -10 °C to room temperature for several hours. To protect it from the subsequent reaction, the carboxy of the 3-side chain, for example, may be esterified. The esterification may be effected by one of the following conventional methods: a method for reacting the carboxylic acid with an alcohol such as methanol, ethanol, n-propanol, isopropanol, butanol or pentanol in the presence of a catalyst, as required, such as dry hydrogen chloride or concentrated sulfuric acid; a method for reacting a halogenide prepared from the carboxylic acid with an alcohol as cited above in the presence of a base such as N,N-dimethylaniline, pyridine, or sodium hydroxide; a method employing a metal alkoxide; a method employing diazomethane; and a method employing dimethyl sulfuric acid and diazabicyclononene or diazabicycloundecene. In this step of the Wittig reaction, the Z-form alone or a mixture of the Z- form and E-form is produced under certain reaction conditions. (Step 2) In this step, the hydroxy of the compound IV is oxidized to give the compound III . This step can be carried out by oxidizing the hydroxy into the carboxy directly or through an aldehyde. As an oxidizing agent, a chromate-type agent such as Jones' reagent, Collins' reagent, pyridinium chlorochromate or pyridimium dichromate, or dimethylsulfoxide combined with sulfur trioxide, trifluoroacetic anhydride, methanesulfonic anhydride, thionyl chloride or oxalyl chloride or the like may be used. In a case where dimethylsulfoxide is used as an oxidizing agent, a tertiary amine, e.g., triethylamine or pyridine may be used as a decomposing agent. As a solvent, a chlorinated hydrocarbon such as chloroform or dichloromethane, an ether such as diethyl ether or tetrahydrofuran, or dimethylformamide or acetone may be used depending on the property of the agent used. The reaction may be carried out under cooling or at room temperature over several hours. (Step 3) In this step, the 2-carboxy group of the compound III is converted into the acid azide, which is then rearranged into the isocyanate, which is then allowed to react with an alcohol to yield the urethane II . This step can be achieved by the Curtius rearrangement; that is, the acid azide compound may be prepared by the reaction of sodium azide with either the acid chloride or the active ester of the compound III; the acid chloride may be prepared by treating the carboxy group with thionyl chloride, phosphoryl chloride, or phosphorus pentachloride; the active ester may be prepared by allowing the carboxy group to react with ethyl chloroformate or isobutoxycarbonyl chloride in the presence of a basic catalyst such as triethylamine or 4-dimethylaminopyridine in a solvent such as acetone, dimethylformamide, dimethylsulfoxide, ethyl acetate, or tetrahydrofuran for several tens of minutes to several hours, under cooling. The isocyanate can be prepared by refluxing the acid azide compound in benzene, toluene, or diphenyl ether for several tens of minutes to several hours. The alcohol which reacts with the isocyanate includes those giving a urethane which might readily yield the desired primary amine, for example, isobutanol, tert-butanol, diisopropylmethanol, cyclopentanol, cyclohexanol, benzyl alcohol, diphenylmethanol or triphenylmethanol. This reaction can be achieved by several hours reflux in a solvent such as an aromatic solvent, e.g., benzene, on chlorinated hydrocarbon, ( e.g., dichloromethane, chloroform), ethyl acetate, acetone or the like in the presence of a base such as triethylamine, 4-dimethylaminopyridine, or 4-pyrrolidinopyridine, as required. (Step 4) In this step, the compound II is allowed to react in the following manner to give the compound I of the present invention. This step also provides, if desired, the means of obtaining the free amino compound previously referred to herein as the "starting material" in process A. The removal of the amino protecting group is achieved by a conventional method, for example, hydrolysis with an acid such as hydrochloric acid or sulfuric acid or a base such as sodium hydroxide, potassium hydroxide or barium hydroxide, decarboxylation with trifluoroacetic acid, hydrogenolysis, or the like. The product can be used in the form of an ammonium salt in the subsequent step, and if necessary, it may be converted into the free amine by the treatment with an adequate base such as sodium carbonate or sodium bicarbonate. The subsequent reaction to give the sulfonamide derivatives is achieved with a substituted sulfonyl halide which has a desired substituent, such as lower alkyl sulfonyl halide ( e.g., methanesulfonyl chloride, methanesulfonyl bromide, ethanesulfonyl chloride, ethanesulfonyl bromide, propanesulfonyl chloride, isopropanesulfonyl chloride, butanesulfonyl chloride, butanesulfonyl bromide, tert-butanesulfonyl chloride or the like), aralkyl sulfonyl halide ( e.g., benzenesulfonyl chloride, phenethylsulfonyl chloride, 3-phenylpropanesulfonyl chloride or the like), aryl sulfonyl halide ( e.g., benzenesulfonyl chloride, benzenesulfonyl bromide, naphthylsulfonyl chloride, naphthylsulfonyl bromide or the like) or substituted aryl sulfonyl halide ( e.g., 4-tolyl chloride, 4-tolyl bromide, 4-ethylbenzenesulfonyl chloride, 4-biphenylsulfonyl chloride, 4-nitrobenzenesulfonyl chloride, 4-methoxybenzenesulfonyl chloride, 4-fluorobenzenesulfonyl chloride, 4-fluorobenzenesulfonyl bromide, 4-acetoxybenzenesulfonyl chloride), usually in the presence of a base such as pyridine or triethylamine in a solvent such as a chlorinated hydrocarbon, e.g., chloroform or dichloromethane, an ether, e.g., ethyl ether or tetrahydrofuran, or an aromatic hydrocarbon, e.g., benzene, at room temperature for several tens of minutes. In this reaction, a carboxylic acid ester I-a which is a compound of the present invention is prepared. The carboxylic acid ester I-a may be converted into the free carboxylic acid I-b , a compound of the present invention, in a conventional manner for the hydrolysis of esters (other ester functions, if any, are also hydrolyzed.) In carrying out the hydrolysis, a catalyst such as hydrochloric acid, sulfuric acid, sodium hydroxide, potassium hydroxide or barium hydroxide may be used. As a solvent, methanol-water, ethanol-water, acetone-water, or acetonitrile- water may be used. If necessary, the free carboxylic acid I-b is converted into a salt of the carboxylic acid I-c , a compound of the present invention represented by the general formula (I), by treating in the conventional manner using a base such as eg., sodium methoxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, dicyclohexylamine, methylmorpholine, pyridine, triethylamine, lysine or arginine. Process-2 (Preparation of Ib, Ic or Id) (Step 1') In this step, an allyl group is introduced into the active methylene of the compound XI . As an allylation agent, an allyl halide such as allyl chloride, allyl bromide, or allyl iodide is used. As a catalyst, a relatively strong base such as sodium amide, potassium tert-butoxide, sodium hydride or lithium diisopropylamide may be used. As a solvent, it is desirable to use an ether such as tetrahydrofuran, ethyl ether, glyme or diglyme. The reaction is carried out at a temperature of -78 °C to 25 °C for a period of several minutes to several hours. In this step, a diallyl-product sometimes may also be produced. (Step 2′) In this step, the ketone of the compound X is converted into an oxime. The oxime formation may be carried out using hydroxylamine hydrochloride or O-methylhydroxylamine hydrochloride in the presence of a base. As a base, pyridine, potassium hydroxide, sodium carbonate, sodium acetate or the like may be used and as a solvent, an alcohol, e.g., methanol, ethanol or the like, or water is used singly or as a mixture. The reaction is usually carried out at room temperature or under heating for a period of several tens of minutes to several tens of hours. (Step 3′) In this step, the oxime of the compound IX is reduced to an amine, which is then allowed to react with a substituted sulfonyl halide without purification to give a compound VIII . The reduction is effected with sodium metal, zinc-hydrochloric acid, stannous chloride-hydrochloric acid, sodium-alcohol, lithium aluminium hydride or the like. As a solvent, an ether, e.g., ethyl ether, tetrahydrofuran, diglyme or the like, or alcohol, e.g., ethanol, methanol or the like may be used in this reduction. The reaction may be carried out at room temperature or under refluxing for several hours. The reaction of the amine to the compound VIII may be carried out in the same manner as in Step 4. (Step 4′) In this step, the double bond of the compound VIII is oxidized to form an epoxide to give a compound VII . As an oxidizing agent, a combined reagent of hydrogen peroxide with a transition metal catalyst or a peroxy acid or its ester such as performic acid, peracetic acid, perbenzoic acid, monoperphthalic acid, monopermaleic acid, pertrifluoroacetic acid, metachloroperbenzoic acid or paranitroperbenzoic acid may be used. As a solvent, an ether, e.g., ethyl ether, tetrahydrofuran, or the like, alcohol, e.g. , methanol, ethanol or the like, or chlorinated hydrocarbon, e.g., dichloromethane, chloroform or the like is exemplified. The reaction may be carried out at a temperature of 0 °C to room temperature for a period of several minutes to several hours. The epoxide prepared in this step may be a mixture of epimers. (Step 5′) In this step, the epoxide VIII is converted into an aldehyde VI (the aforementioned "staring material" of process B) losing one carbon through oxidative cleavage of the glycol produced by hydration. As an oxidizing agent, which also serves as a hydrating catalyst, periodic acid or orthoperiodic acid may be used. It is desirable to use a solvent which is miscible with water, such as an ether, e.g., ethyl ether, tetrahydrofuran, dioxane or the like, or alcohol, e.g., ethanol or the like. The reaction may be carried out at room temperature for a period of several tens of minutes to several hours. The compound VIII can be converted into the compound VI in one step by ozonolysis which attains simultaneously the reactions of Steps 4′ and 5′. (Step 6′) In this step, the aldehyde VI or its cyclic equivalent is allowed to react with an ylide to give the compound (I) of the present invention. This step may be carried out in accordance with Step 1. The prepared carboxylate I-a or free carboxylic acid I-b , the compound of present invention, is converted into a salt or the carboxylic acid I-c by treatment in accordance with Step 4. In the process scheme, R₁ and R₂ each has the same meaning as defined above. R₃ is a carboxy protecting group ordinarily used, for example, alkyl ( e.g., diisopropylmethyl, isobutyl, tert-butyl or the like), cycloalkyl ( e.g., cyclopentyl or the like), aryl ( e.g., benzyl or the like) or aralkyl ( e.g., diphenylmethyl or the like). The wavy line indicates the R or S configuration or their mixture. The salts of the compounds of the general formula (I) are the same as mentioned above. Starting compounds used in the present invention can be prepared in the method described in Helv. Chim. Acta., 66 , 989 (1983) or J. Org. Chem., 50 , 1904, (1985). The following Examples and physical constants are included to explain embodiments of the present invention in more detail, but these are not intended to limit the scope of the invention. Preparation of Intermediate 1-(1) Methyl (-)-5(Z)-7-[(1S, 2S, 3S, 5S)-2-hydroxymethyl-6, 6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoate 2a A mixture of 4 g of 60 % sodium hydride dispersed in mineral oil and 100 ml of dimethylsulfoxide is stirred at 80 °C in atmosphere of nitrogen for about 1 hour until the generation of hydrogen gas ceases. After cooling to room temperature, a solution of 22.15 g of (4-carboxybutyl)triphenylphosphonium bromide in 60 ml of dimethylsulfoxide is added and the mixture is stirred for 15 minutes. To the above mixture is added a solution of 3.73 g of (-)-(4aR, 6S, 8S, 8aS)-7,7-dimethyl-6,8-methanoperhydroisochroman-3-ol 1a in 50 ml of dimethylsulfoxide and the mixture is stirred at room temperature for 2.5 hours. The reaction mixture to which is added 300 ml of ice-chilled water is extracted with 200 ml of ether. The aqueous layer which is adjusted to about pH 3 with 10 % hydrochloric acid is extracted with 300 ml of ether and the ether layer is washed with water. To the ether extract cooled with ice-water is added an excess amount of a diazomethane ether solution and the mixture is stirred for 10 minutes. The reaction mixture is evaporated and the residue is purified by flash column chromatography (240 g of silica gel, 230-400 mesh, eluted with hexane-ethyl acetate=4:1 to 2:1) to give 4.01 g of the titled compound 2a as an oil in 71.7 % yield. [α] D : -3.5° (23°C, c 1.060, CH₃OH). IR ν max(film): 3430, 1740 cm⁻¹. NMR δ ppm (CDCl₃):0.87(3H,s), 1.11(1H,d,J=9Hz), 1.20(3H,s), 1.32-2.70(16H), 3.54(1H,dd,J=6,10Hz), 3.54(1H,dd,J=6,10Hz), 3.66(3H,s), 3.86(1H,dd,J=6,10Hz), 5.27(2H,m). Anal. Calcd. (%) for C₁₈H₃₀O₃: C 73.43, H 10.27. Found (%): C 73.17, H 10.06. (2) Methyl(+)-5(Z)-7-[(1S, 2R, 3S, 5S)-2-hydroxymethyl-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoate 2b Compound 1b is allowed to react in the same manner as in 1-(1) to give compound 2b Yield 91.7% [α] D +34.1° (23°C, c 1.309, CH₃OH). IR ν max(film): 3440, 1742 cm⁻¹. NMR δ ppm (CDCl₃): 0.85(1H,d,J=9Hz), 0.94(3H,s), 1.19(3H,s), 1.35∼2.5 (16H), 3.57(2H,d,J=7Hz), 3.65(3H,s), 5.43(2H,m). Anal. Calcd. (%) for C₁₈H₃₀O₃: C 73.43, H 10.27. Found (%): C 73.22, H 10.38. (3) Methyl (-)-5(Z)-7-[(1R, 2S, 3R, 5R)-2-hydroxymethyl-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoate 2e Compound 1e is allowed to react in the same manner as in 1-(1) to give compound 2e . Yield 75.6 % [α] D -32.3° 23°C, c 1.042, CH₃OH). IR and NMR data of compound 2e are identical with those of compound 2b [prepared in 1-(2)]. Preparation of Intermediate 2-(1) Methyl 5(Z)-7-[(1S, 2S, 3S, 5S)-2-carboxy-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoate 3a To a solution of 2.10 g of alcohol 2a [prepared in 1-(1)] in 20 ml of acetone is dropwise added 3.8 ml of 3 M Jones' reagent at 0 °C under stirring and the mixture is stirred at 0 °C for 1 hour. Water is added to the reaction mixture to dissolve solid material and the mixture is extracted with ether. The extract is washed well with water, dried over anhydrous sodium sulfate and evaporated under reduced pressure to give 2.12 g of the titled compound 3a , which is used in the next reaction without further purification, in 96.6 % yield. IR ν max(film):1740, 1706 cm⁻¹. NMR δ ppm(CDCl₃):0.90(3H,s), 1.22(3H,s), 1.4∼2.7(15H), 3.18(1H,m), 3.65(3H,s), 5.35(2H,m), 8.95(1H,br.s). (2) Compound 2b [prepared in 1-(2)] is allowed to react in the same manner as in 2-(1) to give compound 3b . Yield 93.4 % IR ν max(film):1740, 1700 cm⁻¹. NMR δ ppm(CDCl₃):0.88(3H,s), 0.94(1H,d,J=10Hz), 1.20(3H,s), 1.4∼2.9 (15H), 3.64(3H,s), 5.43(2H,m), 9.70(1H,br.s). (3) Compound 2e [prepared in 1-(3)] in the same manner as in 2-(1) to give compound 3e Yield 97.7 %. IR and NMR data are identical with those of compound 3b . (4) Methyl 5(Z)-7-[(1S, 2S, 3R, 5S)-2-carboxy-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoate 3c To a solution of 1.0 ml of oxalyl chloride in 25 ml of dichloromethane are dropwise added a solution of 1.7 ml of dimethylsulfoxide in 15 ml of dichloromethane at -60 °C under stirring and then a solution of 3.0 g of alcohol 2d in 30 ml of dichloromethane at the same temperature and the mixture is stirred for 1 hour. A solution of 9 ml of triethylamine in 15 ml of dichloromethane is added thereto and the mixture is slowly warmed up to room temperature. The reaction mixture is poured into water and the organic layer is separated. The aqueous layer is extracted with dichloromethane. The combined organic layers are washed with water, dried over anhydrous sodium sulfate and evaporated under reduced pressure to give the corresponding 2α,3α-aldehyde. This crude aldehyde is dissolved in 40 ml of 0.375 M solution of sodium methoxide in 40 ml of methanol and the mixture is allowed to stand at room temperature for 1 hour. The mixture is acidified with dilute hydrochloric acid and extracted with dichloromethane. The extract is washed with water, dried over anhydrous sodium sulfate and evaporated under reduced pressure to give the trans-aldehyde, which is oxidized with Jones' reagent in the same manner as in 2-(1). The prepared crude carboxylic acid 3c is purified by frash column chromatography on silica gel. Yield 70.1 % [α] D -47.4° (20°C, c 1.474, CH₃OH). IR ν max(film):1741, 1702 cm⁻¹. NMR δ ppm(CDCl₃):0.82(3H,s), 1.22(3H,s), 1.4∼2.2(16H), 3.67(3H,s), 5.43(2H,m), 9.73(1H,br.s). Anal. Calcd. (%) for C₁₈H₂₈O₄: C 70.10, H 9.15. Found (%): C 69.74, H 9.14. Preparation of Intermediate 3. Methyl (+)-5(Z)-7-[(1R, 2S, 3S, 5S)-2-(tert-butoxycarbonylamino)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoate 4a To a solution of 2.063 g of carboxylic acid 3a [prepared in 2-(1)] in 8 ml of acetone and 1.5 ml of water are dropwise added a solution of 1.4 ml of triethylamine in 3 ml of acetone, and a solution of 1.0 g of ethyl chlorocarbonate in 2 ml of acetone, successively, at 0 °C under stirring and the mixture is stirred at the same temperature for 1 hour. A solution of 1.0 g of sodium azide in 4 ml of water is added and the mixture is stirred at 0 °C for 1 hour. To a reaction mixture is added 10 ml of water and the mixture is extracted with ethyl ether. The extract is washed with water, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue is dissolved in 50 ml of benzene, then refluxed for 30 minutes with heating, and evaporated. The residue is dissolved in 30 ml of tert-butyl alcohol, further refluxed with heating for 72 hours and evaporated. The resulting residue is purified by frash column chromatography (45 g of silica gel, 230 - 400 mesh, eluted with hexane-ethyl acetate = 6:1) to give the titled compound 4a as an oil. Each compound 3b , 3c and 3e is allowed to react in the same manner as mentioned above to give compound 4b , 4c and 4e , respectively. The results are shown in Table 1. Example 1 Methyl (+)-5(Z)-7-[(1R, 2S, 3S, 5S)-2-benzenesulfonamido-6, 6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoate 5a-a To 1.25 g of the BOC compound 4a (prepared in 3) is added 10 ml of trifluoroacetic acid at room temperature, the mixture is stirred for 30 minutes and the solvent is evaporated. The residue is dissolved in 15 ml of dichloromethane, 600 mg of benzenesulfonyl chloride and 3 ml of triethylamine are added thereto and the mixture is stirred at room temperature for 20 minutes. The reaction mixture is washed with water, dried over anhydrous sodium sulfate and evaporated. The residue is purified by frash column chromatography [45 g of silica gel, 230 - 400 mesh, eluted with hexane -ethyl acetate = 4:1]. The eluate is evaporated to give crystals, which are washed with hexane to give the titled compound 5a-a . Yield 78.6 % Mp. 55 °C. [α] D +52.7° (23°C, c 1.094, CH₃OH). IRνmax(KBr): 3280, 1735, 1337, 1320, 1167, 1157 cm⁻¹. NMR δ ppm(CDCl₃: 0.84(3H,s), 0.96(1H,d,J=10Hz), 1.07(3H,s), 1.2∼2.5 (14H), 3.66(3H,s), 3.90(1H,m), 4.86(1H,d,J=10Hz), 5.23(2H, m), 7.35∼7.66 (3H,m), 7.80∼7.91 (2H,m). CD λ mm (Δ ε )CH₃OH: 269.5 (+0.297), 262.5 (+0.358), 255.5 (+0.345), 222 (+5.03). Anal. Calcd. (%) for C₂₃H₃₃NO₄S: C 65.84, H 7.93, N 3.34, S 7.64. Found (%):C 65.77, H 7.85, N 3.34, S 7.59. Example 2 Methyl 5(Z)-7-[(1R,2R,3S,5S)-2-(3-chlorobenzenesulfonylamido)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoate 5b-f The compound 5b-f can be prepared in the same manner as in Example 1. To 0.5 ml of solution of 500 mg of BOC compound 4b (Table 1) in dichloromethane is added 1 ml of trifluoroacetic acid and the mixture is stirred for 30 minutes. The solvent is evaporated under reduced pressure and the residue is dissolved in ether. The resulting solution is washed with a 10 % sodium carbonate anqueous solution, a saturated aqueous solution of sodium chloride, successivly, dried on anhydrous sodium sulfate, and evaporated under reduced pressure. To the residue dissolved in 10 ml of dichloromethane is added 1 ml of triethylamine and 428 mg of 3-chlorobenzenesulfonyl chloride is added thereto at 0 °C. The mixture is stirred for 1 hour. Ether is added to the reaction mixture, which is then washed with 10 % hydrochloric acid, a saturated aqueous solution of sodium hydrogencarbonate and water, successivly, dried on anhydrous sodium salfate, and distilled under reduced pressure. The residue is purifed by frash column chromatography (25 g of silica gel, eluted with hexane-ethyl acetate =4:1) to give 576 mg of the titled compound 5b-f . The results are shown in Table 2. Example 3 - 21 In the same manner as described in Example 1 or 2, the starting compound 4b , 4c or 4e of which amino protecting group is deprotected to allowed to react with benzenesulfonyl chloride, tosyl chlroide, 4-fluorobenzenesulfonyl chlroide, methanesulfonyl chloride, nitrobenzenesulfonyl chloride, 2-naphthylsulfonyl chloride, benzylsulfonyl chloride, 4-biphenylsulfonyl chloride, 4-metoxybenzenesulfonyl chloride, 3-phenylpropanesulfonyl chloride, 2-phenylethanesulfonyl chloride, 4-chlorobenzenesulfonyl chloride, 2-chlorobenzenesulfonyl chloride, 3-chlorobenzenesulfonyl chloride, 4-ethylbenzenesulfonyl chloride, or 4-acetoxybenzenesulfonyl chloride in the presence of triethylamine in dichloromethane. The compounds shown in Table 2 are prepared. Example 22 (+)-5(Z)-7-[(1R, 2S, 3S, 5S)-2-benzenesulfonamido-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoic acid 6a-a and its sodium salt 7a-a To a solution of 1.58 g of methyl ester 5a-a (prepared in Example 1) in 20 ml of methanol is added 8 ml of 10 % aqueous solution of sodium hydroxide and the mixture is stirred at room temperature for 2 hours. The reaction mixture is acidified with 10 % hydrochloric acid, extracted with ether, washed with water, dried over anhydrous sodium sulfate and evaporated. The residue is purified by frash column chromatograpy [20 g of silica gel, 230 -400 mesh, eluted with hexane - ethyl acetate = 2:1 to 1:1] to give titled compound 6a-a as an oil. Yield 95.3 %. [α] D +48.7° (23°C, c 1.513, CH₃OH). IR ν max(CHCl₃): 3520, 3395, 3265, 1710, 1342, 1158 cm⁻¹. NMR δ ppm(CDCl₃): 0.85(3H,s), 0.98(1H,d,J=10Hz), 1.07(3H,s), 1.3∼2.5 (14H), 3.91(1H,m), 5.23(1H,d, J=7Hz), 5.33(2H,m), 7.33∼7.63 (3H,m), 7.80∼7.91(2H,m), 8.15 (1H,br.s). To a solution of 1.676 g of the above carboxylic acid 6a-a in 10 ml of methanol is added 18.2 ml of 0.221 M solution of sodium methylate in methanol and the solvent is evaporated under reduced pressure. The residue is dissolved in 30 ml of water, treated with active carbon and then lyophilized to give the titled compound 7a-a as powder. IR ν max(KBr): 3300, 1560, 1338, 1308, 1153 cm⁻¹. Example 23 - 43 (1) The reaction is carried out in the same as in Example 22-(1) to yield the compounds shown in Table 3. (2) The reaction is carried out in the same manner as in Example 22-(2) to yield the compounds shown in Table 4. Preparation of Intermediate 4. (1R, 3RS, 5R)-3-(2-propenyl-6,6-dimethylbicyclo[3.1.1]heptan-2-one 12 In nitrogen atmosphere, 115 ml of 1.6 M solution of n-butyllithium in hexane is dropwise added to a solution of 30 ml of diisopropylamine in 40 ml of dry tetrahydrofuran at -30 °C. After the mixture is stirred at -20 °C for 5 minutes, a solution of 18.9 g of (+)-nopinone 11 in 20 ml of dry tetrahydrofuran is dropwise added at -30 °C. After stirred at 0 °C for 10 minutes, the mixture is cooled to -30 °C. Then a solution of 17.5 ml of allyl bromide in 10 ml of dry tetrahydrofuran is dropwise added. After stirred at 35 °C for 30 minutes, the reaction mixture is poured into dilute hydrochloric acid under ice cooling. After the organic layer is separated, the aqueous layer is extracted with ether. The combined organic layers are washed with an aqueous solution of sodium hydrogencarbonate and water, successively, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The residue is fractionally distilled through a fractionation column of about 10 cm length to give 1.90 g of the starting material at 61 - 65 °C/8 mmHg and 16.1 g of the titled compound 12 at 60 - 78 °C/5 mmHg in 13.8 % and 66.0 % yield, respectively. It is considered that the titled compound 12 is a mixture of epimers at 3-position. Anal. Calcd. (%) for C₁₂H₁₈O: C, 80.85;H, 9.96. Found (%): C, 80.59;H, 9.96. The residue is purified by frash chromatography [60 g of silica gel, 230 - 400 mesh, eluted with hexane - ether = 10 : 1] to give 1.10 g of the dipropenyl compound in 3.7 % yield. [α] D +56.4° (23°C, c 1.172, CHCl₃). IR ν max(film):1704 cm⁻¹. NMR δ ppm(CDCl₃): 0.85(3H,s), 1.35(3H,s), 1.8∼2.9(10H), 4.8∼5.3(4H,m), 5.5∼6.2(2H,m). Anal. Calcd. (%) for C₁₅H₂₂O: C, 82.52; H, 10.16. Found (%): C, 81.69; H, 9.91. Preparation of Intermediate 5. O-Methyl oximes of (+)-(1R, 3S, 5S)- and (+)-(1R, 3R, 5S)-3-(2-propenyl)-6,6-dimethylbicyclo[3.1.1]heptan-2-ones 13a and 13b A mixture of 22.6 g of ketone 12 (prepared in 4), 23.8 g of O-methylhydroxylamine hydrochloride, 25 ml of pyridine and 300 ml of ethanol is refluxed with heating for 18 hours and then concentrated under reduced pressure to about 1/3 volume. Ice water is added and the mixture is acidified with dilute hydrochloric acid and extracted with ethyl acetate. The extract is washed with an aqueous solution of sodium hydrogencarbonate and water, successively, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The residue is separated into three isomers shown in Table 5 by frash chromatography (450 g of silica gel, 230 - 400 mesh, eluted with hexane - ether = 20 : 1 to 10 : 1). In the second and third eluates, either syn or anti isomer of compound 13b is eluated. Preparation of Intermediate 6-(1) (-)-(1R, 2S, 3S, 5S)-and (-)-(1R, 2R, 3S, 5S)-2-(benzenesulfonamido)-3-(2-propenyl)-6,6-dimethylbicyclo[3.1.1]heptanes 14c and 14d To 160 ml of solution of 11.4 g of O-methyloxime 13a (prepared in 5) in 99 % ethanol is added 14 g of sodium metal cut into small pieces in small portions over 3 hours under refluxing. The reaction mixture is refluxed with heating until sodium metal completely disappears, then cooled to room temperature and poured into water. The mixture is extracted with ether and the extract is washed with water, dried over anhydrous sodium sulfate and evaporated under reduced pressure. A mixture of the residue, 10 ml of benzenesulfonyl chloride, 26 ml of triethylamine and 165 ml of dichloromethane is allowed to stand at room temperature overnight and then poured into dilute hydrochloric acid under ice cooling. The organic layer is separated and the aqueous layer is extracted with dichloromethane. The combined extracts are washed with an aqueous solution of sodium hydrogencarbonate and water, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue is purified by frash chromatography (300 g of silica gel, 230 - 400 mesh, eluted with hexane - ethyl acetate = 4 : 1) to give two types of isomers 14c and 14d . Compound 14c Yield 17.1 % [α] D -32.0° (22°C, c 1.233, CHCl₃). IR ν max(film): 3330, 1342, 1162 cm⁻¹. NMR δ ppm(CDCl₃): 0.93(3H,s), 1.04(3H,s), 0.7∼2.8(9H), 3.95(1H, m), 4.82 (1H,d,J=9Hz), 4.90(1H,s), 5.00 (1H,s), 5.11(1H,s), 5.75(1H,m), 7.4∼7.6(3H,m), 7.7∼8.0(2H,m). Compound 14d Yield 75.5 % Mp. 93 °C (benzene) [α] D -33.9° (22 °C, c 1.144, CHCl₃). IR ν max(Nujol): 3260, 1327, 1173 cm⁻¹. NMR δ ppm(CDCl₃): 0.72(3H,s), 1.08(3H,s), 1.2-2.5(9H), 3.36 (1H,t,J=8Hz), 4.71(1H,d,J=9Hz), 4.89(1H,s), 5.03(1H,m), 5.70(1H, m), 7.4-7.7(3H,m), 7.8-8.0(2H,m). Anal. Calcd. (%) for C₁₈H₂₅NO₂S,1/2(C₈H₈. H₂O): C 68.63, H 7.95, N 3.81, S 8.72. Found (%): C 68.53, H 7.61, N 3.95, S 8.89. (2) Compound 13b is allowed to react in the same manner as in 6-(1) to give compound 14b . Mp. 57∼58 °C (hexane). [α] D +22.6° 22°C, c 1.353, CHCl₃). IR ν max(Nujol): 3295, 1330, 1163 cm⁻¹. NMR δ ppm(CDCl₃): 0.69(1H,d,J=10Hz), 1.00(3H,s), 1.08(3H,s), 1.3∼1.6(1H, m), 1.7∼2.3(7H,m), 3.35(3H,m), 4.80(1H,dd,J=9,3Hz), 4.96(1H, s), 5.14(1H,d,J=9Hz), 5.4∼5.9 (1H,m), 7.4∼7.6(3H,m), 7.8∼8.2 (2H,m). Anal. Calcd. (%) for C₁₈H₂₅NO₂S: C 67.68, H 7.89, N 4.38, S 10.04. Found (%):C 67.44, H 7.94, N 4.43, S 9.85. Preparation of Intermediate 7. (-)-(1R, 2S, 3S, 5S)-2-Benzenesulfonamido-3-[(2RS)-2,3-epoxypropyl]-6,6-dimethylbicyclo[3.1.1]heptane 15c To a solution of 0.855 g of olefin 14c (prepared in 6) in 13 ml of dichloromethane is added 1.2 g of m-chloroperbenzoic acid in small portions under ice cooling. The reaction mixture is stirred at room temperature for 5 hours and insoluble material is filtered off and washed with dichloromethane. The filtrate is washed with an aqueous solution of sodium thiosulfate, an aqueous solution of sodium hydrogencarbonate and water, successively, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The residue is crystallized from benzene to give 0.95 g of the titled compound 15c . Yield 95.5 %. Mp. 127∼131 °C. [α] D -34.7° (22°C, c 1.027, CHCl₃). NMR data indicate that compound 15c is a mixture of epimer. IR ν max(Nujol): 3260, 1328, 1172 cm⁻¹. NMR δ ppm(CDCl₃): 0.72(3H,s), 1.05, 1.07(total 3H,s), 1.3-2.2(9H), 2.38 (1H,m), 2.72(1H,m), 2.86(1H,m), 3.33(1H,m), 4.80, 4.88(total 1H,d,J=8Hz), 7.4∼7.6(3H,m), 7.7∼8.0(2H,m). Anal. Calcd. (%) for C₂₁H₂₇NO₃S.1/2C₅H₅: C, 67.53; H, 7.28; N, 3.75; S, 8.58. Found (%): C, 67.13; H, 7.51; N, 3.85; S, 8.57. Preparation of Intermediate 8. (-)-(1R, 2S, 3S, 5S)-2-[2-Benzenesulfonamido-6,6-dimethylbicyclo[3.1.1]hept-3-yl]acetoaldehyde 16c To a solution of 0.938 g of epoxide 15c (prepared in 7) in 10 ml of dioxane is dropwise added 3 ml of aqueous solution of 1.2 g of periodic acid at room temperature and the mixture is stirred at room temperature for 4 hours. The reaction mixture is washed with water, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. After the residue is purified by frash chromatography (silica gel, 230 - 400 mesh, eluted with hexane - ethyl acetate = 3 : 2), the eluate is crystallized from hexane to give 445 mg of the titled compound 16c in 49.5 % yield. Mp. 108-110 °C. IR: ν max(Nujol):3215, 1704, 1328, 1151 cm⁻¹. NMR δ ppm(CDCl₃: 0.70(3H,s), 1.06(3H,s), 1.3∼2.9(9H), 3.33(1H,t,J=9Hz), 4.87(1H,d,J=9Hz), 7.4∼7.6(3H, m), 7.7∼7.9(2H,m), 9.70(1H,s). Anal. Calcd. (%) for C₁₇H₂₃NO₃S: C, 63.52; H, 7.21; N, 4.36; S, 9.97. Found (%):C, 63.21; H, 7.23; N, 4.29; S, 9.73. Preparation of intermediate 9. (-)-[(1R, 2R, 3R, 5S)-2-[2-Benzenesulfonamido-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-acetoaldehyde 16b Compound 14b [prepared in 6-(1)] is allowed to react in the same manner as in 7 to give compound 15b as an oil, which is allowed to react in the same manner as in 8 without further purification to give compound 16b . Compound 16b NMR δ ppm(CDCl₃): 0.72(1H,d,J=10Hz), 1.04(3H,s), 1.10(3H,s), 1.7∼2.8 (8H), 3.35(1H,dd,J=8,3Hz), 3.69 (3H,s), 5.17(1H,d,J=8Hz), 7.4∼7.7(3H,m), 7.80∼8.0(2H,m), 9.62 (1H,d,J=2Hz). Example 16 (1) (-)-5(Z)-7-[(1R, 2R, 3R, 5S)-2-Benzenesulfonamido-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoic acid 6d-a and its sodium salt 7d-a Compound 14d [prepared in 6-(1)] is allowed to react according to the manners of 7, 8, 1 and Example 8-(1) to give compound 6d-a as an oil. Compound 6d-a [α] D -4.7° (20°C, c 0.706, CH₃OH). IR ν max(film):3300, 1708, 1341, 1156 cm⁻¹. NMR δ ppm(CDCl₃): 0.81(3H,s), 1.03(3H,s), 1.2∼2.7(15H), 3.96(1H, m), 5.43(2H,m), 7.4∼7.6(3H,m), 7.7∼7.9(2H,m), 8.68(1H, br.s). (2) Sodium salt 7d-a Compound 6d-a is treated in the same manner as in Example 8-(2) to give sodium salt 7d-a . IR ν max(KBr): 3290, 1565, 1322, 1159 cm⁻¹. Example 17 (1) (+)-5(E)-7-[(1R, 2R, 3S, 5S)-2-Benzenesulfonamido-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoic acid 9b-a and its sodium salt 10b-a . Compound 16b is treated in the same manner as in 1 and Example 8-(1) to give 6b-a and 9b-a . Compound 9b-a [α] D +26.5° (20°C, c 1.208, CH₃OH). IR ν max(film):3285, 1708, 1323, 1160 cm⁻¹. NMR δ ppm(CDCl₃):0.70(1H,d,J=8Hz), 1.00(3H,s), 1.08(3H,s), 1.2∼2.5(14H), 3.37(1H,m), 4.89(1H,d,J=8Hz), 5.27(2H,m), 7.3∼7.7 (3H,m), 7.8∼8.0(2H,m). (2) Sodium salt 10b-a Compound 9b-a is treated in the same manner as in Example 8-(2) to give sodium salt 10b-a . IRνmax(KBr):3290, 1565, 1322, 1306, 1159, 967 cm⁻¹. Example 44 p-Methoxybenzylamine (+)-5(Z)-7-[(1R,2R,3S,4S)-2-benzenebicyclo[3.1.1]hept-3-yl]-5-heptenoate 17b-a To a suspension of 36.46 g of (4-carboxybutyl)triphenylphosphonium bromide in 160 ml of dry tetrahydrofuran is added 18.46 g of potassium tert-butoxide under stirring in an nitrogen atmosphere and the mixture is stirred for 2 hours to prepare Wittig reagent. To the resulting mixture is slowly dropwise added a solution of 9.44 g of aldehyde 16b-a in 60 ml of tetrahydrofuran at 0 °C and the mixture is stirred at the same temperature for 2 hours. The reaction mixture added 200 ml of water is washed with 150 ml of ether twice. The aqueous layer is acidified to about pH 3 with 10 % hydrochloric acid and then extracted with 200 ml of ether twice. The extract is washed successively, with water, an aqueous solution of sodium chloride, dried on anhydrous sodium sulfate, and evaporated under reduced pressure. To the resulting crude carboxylic acid dissolved in 40 ml of ethyl acetate is added 4.03 g of 4-methoxylbenzylamine in 10 ml of ethyl acetate and the mixture is allowed to stand at room temperature overnight and then filtrated to collect 10.9 g of the crystals which contain about 2 % of E-olefin. The crude salt (41.9 g ) added 200 ml of 5 % hydrochloric acid is extracted with ether. The extract is washed with water, dried, and evaporated to give the carboxylic acid which is treated with 4-methoxybenzylamine again to give 35.2 g of the titled compound 17b-a . The prepared compound is estimated to contain 0.6 % of E-olefine by HPLC. Mp. 125∼127°C. [α] D +27.7 (24°C, c 1.083, CH₃OH). IRνmax(KBr); 1542, 1517, 1309, 1151 cm⁻¹. NMRδppm(CDCl₃) 0.69(1H,d,J=9.8Hz), 1.02(3H,s), 1.11(3H,s), 1.32∼2.37(14H), 3.18(1H,m), 3.78(3H,s), 3.91(1H,d,J=13.8Hz), 3.95 (1H,d,J=13.8Hz), 5.34(2H,m), 5.65(3H,br,s), 6.40(1H,br,s), 6.86 (2H,d,J=8.7Hz), 7.29(2H,d,J=8.7Hz), 7.42∼7.58(3H), 7.90(2H, m). Anal. Calcd. (%) for C₃₀H₄₂N₂O₅S: C 66.39, H 7.80, N 5.16, S 5.91. Found (%): C 66.28, H 7.76, N 5.15, S 5.94. The compounds of the present invention have a potent antagonistic action against the thromboxane A₂ receptor, and strongly inhibit platelet aggregation or vasoconstriction caused by thromboxane A₂. This means that the compounds of the invention are useful as anti-thrombotic and anti-vasoconstricting drugs. The platelet aggregation inhibitory activity of the present invention is shown in the following in vitro tests effected using representative compounds of the present invention. [Material tested and Method] From the abdominal artery of a male rat (Sprague-Dowley, 8 weeks old) was collected 10 ml of blood with a syringe containing 1.5 ml of ACD (85 mM sodium citrate, 70 mM citric acid, 110 mM glucose) and 20 µg of prostaglandin E₁. The blood is placed in a plastic test tube, mixed by moderate turning and centrifuged for 10 minutes at 160 x g to give platelet rich plasma (PRP). To the prepared PRP was added apyrase (25 µg/ml) and the mixture was layered on 40 % bovine serum albumin. The resulting mixture is centrifuged at 1200 x g for 25 minutes. The platelet pellet suspended in a small amount of a buffer (137 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl₂, 3.8 mM NaH₂PO₄, 3.8 mM Hepes, 5.6 mM glucose, 0.035% bovine serum albumin, pH 7.35) was applied on 10 ml of Sepharose 2B column and eluted with the buffer to prepare a washed platelet. The platelet aggregation reaction was measured by an aggregometer (NKK HEMA TRACER 1 MODEL PAT-6A.6M, Niko bioscience). In a measuring cuvette was placed 245 µl of the washed platelet of which platelet number was adjusted to 5 x 10⁵/µl and set in the aggregometer. The washed platelet was stirred (1000 rpm) at 37 °C and 3.8 µl of 0.1 M of CaCl₂ was added thereto. One minutes after, 0.5 µl of a solution of test compound (dimethylsulfoxide solution) was added and 2 minutes after, 1 µl of Collagen reagent Horm® [HORMON-CHEMIE München GMBH, final concentrate 4 µg/ml) as a platelet aggregating agent was added. The change in light transmittance caused by platelet aggregation was recorded against time elasped. 50 % aggregation inhibitory rate was calculated from the aggregation inhibitory rate (which was measured 3 minutes after adding a platelet aggregating agent). The light transmittance for the washed platelet and the buffer were setted at 0 % and 100 %, respectively. The results of the test are shown in Table 6. The objective compounds of this invention show a potent inhibitory activity against platelet aggregation caused by collagen. The objective compounds of the present invention strongly inhibit thromboxane induced platelet aggregation, vasoconstriction, and bronchoconstriction. Therefore, the human or animal clinical application of such pharmacological actions of the compounds can be expected, that is, the compounds can be used for treatment or improvement of such symptoms as arteriosclerosis, myocardial infarction, acute ischemic angina pectoris, circulatory shock, sudden death and so forth. The objective compounds of the present invention can be administered orally or parenterally. For example, the compounds can be formulated into tablets, capsules, pills, granules, fine subtilaes, solutions, emulsions, suppositories, and injections for intravenous, intramuscular, subcutaneous administration. In preparing the therapeutic preparations of the compounds, adequate carriers and fillers are selected from conventionally used carriers and fillers. The objective compounds of the present invention may be administered in a dose of about 10 to 800 mg per day for an adult. Thus, the invention provides the use of a compound or salt of the invention in making a medicament. The invention further includes a pharmaceutical or veterinary formulation comprising a compound or salt of the invention formulated for pharmaceutical or veterinary use, respectively, and optionally formulated in unit dosage form and/or with an acceptable diluent, carrier or excipient. Such formulations may be made in a manner known to the skilled reader using conventional procedures. Thus, in general the invention also includes a method of making a therapeutic composition for use in humans or other animals, comprising formulating a bulk quantity of a compound or salt of the invention for pharmaceutical or veterinary use, optionally in unit dosage form and/or with an acceptable diluent, carrier or excipient.

Claims: Claims for the following Contracting States : DE,GB,FR,IT,NL,SE,LI,CH,BE,AT,LU A compound of the formula: wherein R₁ is hydrogen or lower alkyl; R₂ is lower alkyl, aralkyl or aryl which may be substituted by lower alkyl, alkoxy, acetoxy, hydroxy, halogen, nitro or phenyl; and the wavy line indicates the R or S configuration or their mixture, with the proviso that the compound is not wherein R₁ is H or CH₃ and R₂ are as defined above. A compound as claimed in Claim 1, wherein R₂ is phenyl optionally substituted by lower alkyl, alkoxy, acetoxy, hydroxy, halogen, nitro or phenyl. A compound as claimed in Claim 1 which is 5(Z)-7-[2-benzenesulfonamido-6,6-dimethylbicyclo[3,1,1]hept-3-yl]-5-heptenoic acid, 5(Z)-7-[6,6-dimethyl-2-(4-tosylamido)bicyclo[3,1,1]hept-3-yl]-5-heptenoic acid, 5(Z)-7-[2-(3-chlorobenzenesulfonamido)-6,6-dimethylbicyclo[3,1,1]hept-3-yl]-5-heptenoic acid, or 5(Z)-7-[6,6-dimethyl-2-(4-hydroxybenzenesulfonamidobicyclo[3,1,1]hept-3-yl]-5-heptenoic acid. A salt of a compound as claimed in any one of Claim 1 to 3. A process for preparing a compound of the formula: wherein R₁ is hydrogen or lower alkyl; R₂ is lower alkyl, aralkyl or aryl which may be substituted by lower alkyl, alkoxy, acetoxy, hydroxy, halogen, nitro or phenyl; and the wavy line indicates the R or S configuration or their mixture, which process comprises either: (a) reacting a compound of the formula: wherein R'₁ is lower alkyl and the wavy line is as defined above, or salt thereof, with a compound of the formula Hal-SO₂-R₂, wherein Hal is halogen and R₂ is as defined above, and, if desired subjecting the resulting compound to hydrolysis and/or salt formation; or (b) reacting a compound of the formula: wherein R₂ and the wavy line are each as defined above, or its equivalent, with a compound of the formula: (Ar)₃P=CH-(CH₂)₃COOR₁, wherein Ar is aryl, and R₁ is as defined above, and, if desired, subjecting the resulting compound to esterfication, hydrolysis and/or salt formation. A process as claimed in Claim 5 wherein the starting compound is prepared in a process comprising at least the last step of either of the following reaction schemes: wherein R₁, R₂ and wavy line are as defined in Claim 1. A process as claimed in claim 5 or claim 6 which further comprises the steps of isolating the resultant compound and using said compound in the preparation of a medicament for the treatment of thromboxane related diseases. The use of a compound as defined in any one of Claims 1 to 3 or a salt as defined in Claim 4 in making a medicament. A pharmaceutical or veterinary formulation comprising a compound as defined in any one of Claims 1 to 3 or a salt as defined in Claim 4 formulated for pharmaceutical or veterinary use, respectively, and optionally formulated in unit dosage form and/or with an acceptable diluent, carrier or excipient. A method of making a therapeutic composition for use in humans or other animals, comprising formulating a bulk quantity of a compound of the formula: or a compound as defined in claim 2 or claim 3 or a salt as defined in claim 4 for pharmaceutical or veterinary use, optionally in unit dosage form and/or with an acceptable diluent, carrier or excipient. Claims for the following Contracting States : ES,GR A process for making a pharmaceutical or veterinary preparation for use in the treatment of thromboxane A₂ mediating diseases in mammals, which process comprises admixing a pharmacologically effective amount of at least one compound of the formula: wherein R₁ is hydrogen or lower alkyl; R₂ is lower alkyl, aralkyl or aryl which may be substituted by lower alkyl, alkoxy, acetoxy, hydroxy, halogen, nitro or phenyl; and the wavy line indicates the R or S configuration or their mixture or a salt thereof, with one or more pharmaceutically or veterinarily acceptable carriers, diluents or excipients. A process as claimed in Claim 1 wherein R₂ is phenyl optionally substituted by lower alkyl, alkoxy, acetoxy, hydroxy, halogen, nitro or phenyl. A process as claimed in Claim 1 wherein the compound is 5(Z)-7-[2-benzenesulfonamido-6, 6-dimethylbicyclo-[3,1,1]hept-3-yl]-5-heptenoic acid, 5(Z)-7-[6,6-dimethyl-2-(4-tosylamido)bicyclo[3,1,1]hept-3-yl]-5-heptenoic acid, 5(Z)-7-[2-(3-chlorobenzenesulfonamido)-6,6-dimethylbicyclo[3,1,1]hept-3-yl]-5-heptenoic acid, or 5(Z)-7-[6,6-dimethyl-2-(4-hydroxybenzenesulfonamidobicyclo[3,1,1]hept-3-yl]-5-heptenoic acid. A process for preparing a compound of the formula: wherein R₁ is hydrogen or lower alkyl; R₂ is lower alkyl, aralkyl or aryl which may be substituted by lower alkyl, alkoxy, acetoxy, hydroxy, halogen, nitro or phenyl; and the wavy line indicates the R or S configuration or their mixture, which process comprises either: (a) reacting a compound of the formula: wherein R'₁ is lower alkyl and the wavy line is as defined above, or salt thereof, with a compound of the formula Hal-SO₂-R₂, wherein Hal is halogen and R₂ is as defined above, and, if desired subjecting the resulting compound to hydrolysis and/or salt formation; or (b) reacting a compound of the formula: wherein R₂ and the wavy line are each as defined above, or its equivalent, with a compound of the formula: (Ar)₃P=CH-(CH₂)₃COOR₁ , wherein Ar is aryl, and R₁ is as defined above, and, if desired, subjecting the resulting compound to esterfication, hydrolysis and/or salt formation. A process as claimed in Claim 4 wherein the starting compound is prepared in a process comprising at least the last step of either of the following reaction schemes: wherein R₁, R₂ and wavy line are as defined in Claim 1. A process as claimed in claim 4 or claim 5 which further comprises the steps of isolating the resultant compound and using said compound in the preparation of a medicament for the treatment of thromboxane related diseases. The use of a compound as defined in any one of Claims 1 to 3 or a salt thereof in making a medicament.

Inventors: HAGISHITA, SANJI, SENO, KAORU
Applicants: SHIONOGI SEIYAKU KABUSHIKI KAISHA TRADING UNDER THE NAME OF  SHIONOGI & CO. LTD.
Application year: 1988
Main classification: C07C311
IPC codes: C07C311, A61K31